Nestle SA - Agreement to divest mainstream VMS business

Nestle SA

01/09/2026 18:05

RNS Number : 9848S
  
Nestle SA
  
01 September 2026
  
 


Nestlé Press Release
 
.......................................
 
Vevey/Switzerland, September 1, 2026
 
.......................................
 
[Ad hoc announcement pursuant to Art. 53 LR]
 
Nestlé reaches agreement to divest its mainstream vitamins, minerals and supplements business
 
Nestlé has agreed to divest its mainstream Vitamins, Minerals and Supplements (VMS) business (the 'Holistic Health portfolio') to Yellow Wood Partners for USD 1.0 billion (CHF 0.8 billion). The transaction is subject to applicable regulatory approvals and is expected to close by the first half of 2027.
 
"This is another important step in the strategic transformation of our portfolio" said Philipp Navratil, CEO, Nestlé. "We are focusing our resources where we have the strongest competitive advantage. With Nestlé's strong innovation and brand-building capabilities, we are well positioned for growth in the premium, science-led VMS space, where brands such as Solgar and Pure Encapsulations continue to perform strongly. At the same time, the category has evolved, and the mainstream VMS business requires a different approach under dedicated ownership."
 
The scope of the transaction comprises seven established brands: Nature's Bounty, Osteo Bi-Flex, Ester-C, Gard, Nuun, Puritan's Pride and Sisu, together with the associated US private-label supplements business, dedicated manufacturing, packaging, warehousing and distribution operations. In 2025, the business generated sales of USD 1.2 billion (CHF 1.0 billion). It predominantly operates in the US, with a presence in numerous other countries including Canada and China.
 
 
 
Contacts
 
Media
 
Christoph Meier
Tel.: +41 21 924 2200
mediarelations@nestle.com
 
Investors
 
David Hancock
Tel.: +41 21 924 3509
ir@nestle.com




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
STRAKDBKOBKDNCK